Hi all,
The recent publication of the ACURATE-IDE trial results in The Lancet found that ACURATE neo2 did not meet non-inferiority compared to SAPIEN 3/Ultra and Evolut valves, with significantly higher rates of adverse outcomes including increased mortality, stroke, and rehospitalization.
We’re looking to gather ACURATE neo2 data to conduct a comprehensive real-world evidence study. This would allow us to compare the trial findings with real-world observational data and investigate whether the controlled trial results translate to clinical practice.
If you have ACURATE neo2 patients in your database, please let us know your approximate case volume and data availability. We can share our analysis framework to facilitate collaboration.
Looking forward to hearing from the community!